The Pill That Changed Everything: FDA Approves First All-Oral AML Regimen for Elderly Patients

For decades, the standard of care for older adults with acute myeloid leukemia who could not tolerate intensive chemotherapy meant one thing: frequent trips to an infusion center, intravenous drugs, and a treatment schedule built around the hospital rather than the patient. On May 13, 2026, the FDA changed that calculus entirely.

The agency approved Inqovi (decitabine and cedazuridine) in combination with venetoclax as the first and only all-oral combination treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. The approval, granted to Taiho Oncology, marks a genuine inflection point in how one of the most aggressive blood cancers is managed in the population most likely to be diagnosed with it.

Why This Approval Is Different

AML is not a young person's disease. In 2026, an estimated 22,720 Americans will be diagnosed with it, and more than half of those patients will be ineligible for intensive induction chemotherapy because of advanced age or underlying health conditions. For this population, the existing standard of care has been azacitidine or decitabine delivered intravenously or subcutaneously, combined with venetoclax. The regimen works reasonably well. The problem is how it is delivered. Patients must visit infusion centers repeatedly, often weekly, during a period when their immune systems are compromised and their energy reserves are depleted. The treatment burden is not a minor inconvenience. For elderly patients with limited mobility, caregiving support, or geographic access to specialized oncology centers, it can be a genuine barrier to receiving care at all.

Inqovi solves the delivery problem through a pharmacological workaround that took years to engineer. Decitabine, the active hypomethylating agent, is rapidly broken down in the gut and liver by an enzyme called cytidine deaminase before it can reach systemic circulation in meaningful concentrations. Cedazuridine inhibits that enzyme, allowing oral decitabine to achieve plasma exposures comparable to intravenous administration. The result is a fixed-dose oral tablet that can be taken at home, on days one through five of each 28-day cycle, alongside oral venetoclax. No infusion center required.

What the ASCERTAIN-V Data Show

The approval was supported by results from the Phase 2 ASCERTAIN-V trial, a single-arm, open-label study enrolling 101 adults with newly diagnosed AML who were ineligible for intensive induction chemotherapy. The primary endpoint was complete remission rate and duration of complete remission. Forty-two patients achieved a complete remission, a rate of 41.6 percent, with a median time to CR of two months. The median duration of complete remission was not reached at the time of analysis, with more than 75 percent of patients who achieved CR still in remission at the 12-month mark. Median overall survival was 15.5 months. The CR plus CR with incomplete hematologic recovery rate was 63.4 percent, a key secondary endpoint that captures patients who achieve meaningful disease control even without full blood count recovery.

The safety profile was consistent with what is known about both agents individually. Myelosuppression was the dominant toxicity, with febrile neutropenia occurring in 52 percent of patients and grade 3 or higher adverse events in 98 percent. Thirteen deaths occurred during the trial, three attributed to adverse events and ten to disease progression. These are not trivial numbers, but they reflect the underlying severity of AML in an elderly, comorbid population rather than unexpected drug-related harm. The prescribing information carries warnings for myelosuppression and embryo-fetal toxicity, consistent with the existing Inqovi label for myelodysplastic syndromes.

The Broader Significance of Going Oral

The shift from intravenous to oral delivery in oncology is not merely a convenience story. It is a health equity story. The patients most likely to benefit from this approval are also the patients least likely to have easy access to infusion centers: older adults in rural areas, patients with limited transportation, those whose caregivers cannot take repeated days off work to accompany them to treatment. An all-oral regimen that can be managed at home, with appropriate monitoring, removes a structural barrier that has quietly shaped who receives optimal AML care and who does not.

There is also a clinical rationale for preferring oral administration beyond convenience. Intravenous decitabine requires careful scheduling around clinic capacity and staffing. Oral administration allows for more consistent dosing adherence and reduces the risk of treatment delays caused by logistical factors outside the patient's control. For a disease where treatment interruptions can compromise response, that consistency has real clinical value.

The FDA reviewed the application under Project Orbis, its framework for concurrent international review of oncology drugs, in collaboration with Health Canada. That international coordination reflects the global significance of the approval and accelerates the timeline for patients in Canada to access the same regimen. Inqovi also received Orphan Drug Designation for this indication, recognizing the unmet need in a patient population that has historically been underserved by clinical trial design and drug development investment.

What Comes Next

The approval does not resolve every challenge in AML management for elderly patients. The ASCERTAIN-V trial was a single-arm study without a direct randomized comparison to the intravenous azacitidine plus venetoclax regimen that currently dominates clinical practice. Oncologists will need to make their own assessments about how the efficacy data compare across trials conducted in similar but not identical patient populations. The high rate of serious adverse events, while expected in this disease context, means that patients will still require close monitoring and access to supportive care infrastructure even if they are not receiving treatment in an infusion center.

What the approval does establish, unambiguously, is that the pharmacological barrier to oral hypomethylating therapy in AML has been cleared. The cedazuridine inhibition strategy that Taiho pioneered for MDS and CMML has now been validated in a more aggressive hematologic malignancy, with efficacy data sufficient to support regulatory approval. That proof of concept has implications beyond this specific regimen. It demonstrates that the oral delivery problem for this class of drugs is solvable, and it sets a precedent for future combinations that may build on the same platform.

For the roughly 11,000 Americans diagnosed with AML each year who are not candidates for intensive chemotherapy, the approval means that the conversation with their oncologist now includes an option that did not exist before. That option comes with real toxicity and real monitoring requirements. But it also comes with the possibility of receiving treatment at home, on a schedule that fits their lives rather than the other way around. In a disease defined by its urgency and its demands, that possibility is not a small thing.